Gladius Pharmaceuticals Corporation
Records under this name other than patents Gladius Pharmaceuticals Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Gladius Pharmaceuticals Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,975,905 | Derivatized 3-styryl-cephalosporins Lapsed on the fee record Ended May 22, 2026 · USPTO record | Lapsed on the fee record | Ended May 22, 2026 | USPTO record |
| US 11,028,103 | Derivatized 3-styryl-cephalosporins Lapsed on the fee record Ended Jun 8, 2025 · USPTO record | Lapsed on the fee record | Ended Jun 8, 2025 | USPTO record |
| US 10,239,890 | Broad spectrum beta-lactamase inhibitors Lapsed on the fee record Ended Mar 26, 2023 · USPTO record | Lapsed on the fee record | Ended Mar 26, 2023 | USPTO record |
| US 8,883,772 | Broad spectrum beta-lactamase inhibitors Lapsed on the fee record Ended Nov 11, 2022 · USPTO record | Lapsed on the fee record | Ended Nov 11, 2022 | USPTO record |
| US 10,000,509 | Broad spectrum beta-lactamase inhibitors Lapsed on the fee record Ended Jun 19, 2022 · USPTO record | Lapsed on the fee record | Ended Jun 19, 2022 | USPTO record |
| US 9,862,729 | Broad spectrum beta-lactamase inhibitors Lapsed on the fee record Ended Jan 9, 2022 · USPTO record | Lapsed on the fee record | Ended Jan 9, 2022 | USPTO record |
| US 9,809,605 | Broad spectrum beta-lactamase inhibitors Lapsed on the fee record Ended Nov 7, 2021 · USPTO record | Lapsed on the fee record | Ended Nov 7, 2021 | USPTO record |
| US 9,453,032 | Broad spectrum beta-lactamase inhibitors Formerly held Lapsed on the fee record Ended Sep 27, 2020 · USPTO record | Lapsed on the fee record | Ended Sep 27, 2020 | USPTO record |